Will a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
1
70Ṁ102027
59%
chance
1D
1W
1M
ALL
This is the first the first in vivo CRISPR-based candidate to begin late-stage clinical development. Phase 3 trials expected in late 2023. https://www.europeanpharmaceuticalreview.com/news/187777/regulatory-first-for-gene-editing-therapy/
This question is managed and resolved by Manifold.
Get
1,000 to start trading!
1,000Sort by:
The current price is approximately the percent of drugs entering Phase III trials that become approved: https://www.science.org/content/blog-post/latest-drug-failure-and-approval-rates
That seems reasonable for now, but I'll definitely watching this closely. Thanks for posting this question, I wouldn't have known about this otherwise!
Related questions
Related questions
Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
78% chance
Will there be an in-vivo gene therapy that edits multiple genes at once approved anywhere in the world before 2030?
52% chance
Will gene editing have cured at least one major disease by 2025?
95% chance
Will we have gene therapy for a major strain of Crohn's disease by 2030?
26% chance
Will there be a CRISPR treatment for Ehlers-Danlos Syndromes before 2040?
52% chance
Will Alzheimer’s be curable by 2027?
7% chance
By 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
18% chance
Will there be a cure for Prion diseases by 2025
1% chance
Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?
Will there be a credible (see details) announcement of human multiplex gene editing (≥5 genomic loci) pre 2026?
34% chance